{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:55:30Z","timestamp":1776873330433,"version":"3.51.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Regorafenib belongs to a sub-group of small-molecule multi-targeted tyrosine kinase inhibitors(TKIs). In various studies with respect to the side-effect of regorafenib, drug-associated proteinuria standardly qualified to be defined as nephrotic syndrome was rarely reported as well as the relation of regorafenib with the occurrence and development of thrombotic microangiopathy (TMA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this case report and literature review, we presented a 62-year-old patient receiving regorafenib for metastatic colon cancer, manifesting abundant proteinuria, in which TMA was also diagnosed through renal biopsy. As far as we were concerned, this was the first reported in terms of regorafenib-induced TMA confirmed by renal biopsy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case indicates that regorafenib, a kind of TKIs may result in TMA, which is a rare but life-threatening complication of cancer treatment drug. Insights from this case might help physicians diagnose rare forms of TMA and adjust treatment for patients in a timely manner.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02656-9","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:03:22Z","timestamp":1647691402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures"],"prefix":"10.1186","volume":"23","author":[{"given":"Qinghua","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"1","key":"2656_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer. 2011;129(1):245\u201355. https:\/\/doi.org\/10.1002\/ijc.25864.","journal-title":"Int J Cancer"},{"issue":"2","key":"2656_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","volume":"50","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension[J]. Am J Kidney Dis. 2007;50(2):203\u201318. https:\/\/doi.org\/10.1053\/j.ajkd.2007.04.025.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2656_CR3","doi-asserted-by":"publisher","first-page":"c312","DOI":"10.1159\/000319885","volume":"117","author":"KD Jhaveri","year":"2011","unstructured":"Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature[J]. Nephron Clin Pract. 2011;117(4):c312\u20139. https:\/\/doi.org\/10.1159\/000319885.","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"2656_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Bollee","year":"2009","unstructured":"Bollee G, Pate N, Cazajous G, Robert C, Goujon JM, Fakhouri F, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib[J]. Nephrol Dial Transplant. 2009;24(2):682\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfn657.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2656_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","volume":"61","author":"E Wallace","year":"2013","unstructured":"Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H. Dasatinib-induced nephrotic-range proteinuria[J]. Am J Kidney Dis. 2013;61(6):1026\u201331. https:\/\/doi.org\/10.1053\/j.ajkd.2013.01.022.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2656_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.xkme.2020.11.011","volume":"3","author":"A Strasma","year":"2021","unstructured":"Strasma A, Coke H, Mamlouk O, Tchakarov A, Mandayam S. Lupus-like glomerulonephritis associated with regorafenib, a multikinase inhibitor[J]. Kidney Med. 2021;3(2):294\u20138. https:\/\/doi.org\/10.1016\/j.xkme.2020.11.011.","journal-title":"Kidney Med"},{"issue":"41","key":"2656_CR7","doi-asserted-by":"publisher","first-page":"67661","DOI":"10.18632\/oncotarget.11813","volume":"7","author":"B Liu","year":"2016","unstructured":"Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients[J]. Oncotarget. 2016;7(41):67661\u201373. https:\/\/doi.org\/10.18632\/oncotarget.11813.","journal-title":"Oncotarget"},{"issue":"3","key":"2656_CR8","doi-asserted-by":"publisher","first-page":"e90135","DOI":"10.1371\/journal.pone.0090135","volume":"9","author":"ZF Zhang","year":"2014","unstructured":"Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis[J]. PLoS One. 2014;9(3):e90135. https:\/\/doi.org\/10.1371\/journal.pone.0090135.","journal-title":"PLoS One"},{"issue":"3","key":"2656_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","volume":"33","author":"T Yoshino","year":"2015","unstructured":"Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations[J]. Invest New Drugs. 2015;33(3):740\u201350. https:\/\/doi.org\/10.1007\/s10637-014-0154-x.","journal-title":"Invest New Drugs"},{"issue":"1","key":"2656_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/0971-4065.107215","volume":"23","author":"PK Jha","year":"2013","unstructured":"Jha PK, Vankalakunti M, Siddini V, Bonu R, Prakash GK, Babu K, et al. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy[J]. Indian J Nephrol. 2013;23(1):67\u201370. https:\/\/doi.org\/10.4103\/0971-4065.107215.","journal-title":"Indian J Nephrol"},{"issue":"10","key":"2656_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N. VEGF and the quest for tumour angiogenesis factors[J]. Nat Rev Cancer. 2002;2(10):795\u2013803. https:\/\/doi.org\/10.1038\/nrc909.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2656_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy[J]. Kidney Int. 2014;85(2):457\u201370. https:\/\/doi.org\/10.1038\/ki.2013.344.","journal-title":"Kidney Int"},{"issue":"6","key":"2656_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, Buttner A, Buttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy[J]. Histopathology. 2018;73(6):990\u20131001. https:\/\/doi.org\/10.1111\/his.13716.","journal-title":"Histopathology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02656-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:11:25Z","timestamp":1647691885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02656-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02656-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A family of the participant signed a letter of informed consent to allow her data to be stored, as required by West China Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}